The present invention concerns a conjugate comprising (i) a cell binding agent which binds to the human mucin-1 (MUC1) glycoprotein, linked to (ii) at least one cytotoxic agent, for use in a method for treating cancer, wherein the method comprises at least two cycles, wherein, for each cycle, the conjugate is administered at a dose corresponding to that of an administration schedule of at least 60 mg/m2 every week of the cycle, and wherein the conjugate is administered at least two times during each cycle.本發明涉及一種在用于治療癌症的方法中使用的綴合物,其包含:(i)與人粘蛋白-1(MUC1)糖蛋白結合的細胞結合劑,其與(ii)至少一種細胞毒性劑連接,其中所述方法包括至少兩個周期,其中,在每個周期,所述綴合物以對應于所述周期的每周至少60mg/m2的投予日程的劑量投予,且其中所述綴合物在每個周期期間投予至少兩次。
